People news: Pfizer and GlaxoSmithKline

Share this article:
Pfizer named GSK's Dr. Yvonne Greenstreet SVP, head of medicines development for its Specialty Care Business Unit. Greenstreet spent 18 years at GSK, most recently as SVP chief of strategy, research and development, and led development of small molecules and biologics in several therapeutic areas, including musculoskeletal, immunology/inflammation, gastrointestinal, urology, ophthalmology and anti-infectives, and also headed clinical development and medical affairs for the firm's European business. She succeeds Dr. Michael Berelowitz, who is retiring after 14 years at Pfizer, and she will report to Geno Germano, president and general manager, Specialty Care Business Unit.

Slack and the International Society of Refractive Surgery named James Bradley Randleman, MD editor-in-chief of the Journal of Refractive Surgery. Dr. Randleman is an assistant professor in the Department of Ophthalmology at Emory University.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in People Moves

Monday Moves: October 20

Promotions and hires for agencies and manufacturers

Monday Moves: September 29

Promotions and hires for agencies and manufacturers

Monday Moves—July 21, 2014

Hires and promotions for Manufacturers, Agencies and Media